Emergent BioSolutions (EBS) Misses Q1 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.81 -5.68%
Revenue Growth %: -45.6%
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Revenue Growth %: -45.6%
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of ($0.03), $0.25 worse than the analyst estimate of $0.22. Revenue for the quarter came in at $117.8 million versus the consensus estimate of $140.42 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Cboe Global Markets (CBOE) Tops Q3 EPS by 21c
- Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
